Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Weathers Economic Storm: ICD Biz Stable; A-Fib, Neuro Accelerating

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical said Jan. 27 it has detected no significant impact of the worsening economy on its end-of- year 2008 financial results, reporting growth at or ahead of estimates for all of its business units

You may also be interested in...



Research In Brief

RF ablation for varicose veins: VNUS Medical Technologies' ClosureFAST radiofrequency ablation system for treatment of venous reflux, the underlying cause of symptomatic varicose veins, is "significantly superior" to endovenous laser treatment as measured by quality-of-life and post-procedural recovery parameters, according to results of the 69-patient RECOVERY multicenter, randomized study by Jose Almeida, Miami Vein Center, et al, published in the June issue of the Journal of Vascular & Interventional Radiology. The patients treated with ClosureFAST had less postoperative pain and bruising and better reduction of symptoms than the laser-treated patients as early as two days post-procedure and continued to show better outcomes two weeks after the treatment; however, equalization in most parameters was observed between the two groups by one month. All quality-of-life parameters were significantly better, and minor complications were five times less common, in the ClosureFAST group. Covidien recently signed a deal to acquire VNUS for $440 million (1"The Gray Sheet" May 11, 2009, p. 15)

Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Topics

UsernamePublicRestriction

Register

MT027066

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel